| Harnessing albumin as a carrier for cancer therapies EN Hoogenboezem, CL Duvall Advanced drug delivery reviews 130, 73-89, 2018 | 472 | 2018 |
| Creation of an injectable in situ gelling native extracellular matrix for nucleus pulposus tissue engineering RA Wachs, EN Hoogenboezem, HI Huda, S Xin, SL Porvasnik, ... The Spine Journal 17 (3), 435-444, 2017 | 47 | 2017 |
| Dual carrier-cargo hydrophobization and charge ratio optimization improve the systemic circulation and safety of zwitterionic nano-polyplexes MA Jackson, SK Bedingfield, F Yu, ME Stokan, RE Miles, EJ Curvino, ... Biomaterials 192, 245-259, 2019 | 32 | 2019 |
| Kupffer cell release of platelet activating factor drives dose limiting toxicities of nucleic acid nanocarriers MA Jackson, SS Patel, F Yu, MA Cottam, EB Glass, EN Hoogenboezem, ... Biomaterials 268, 120528, 2021 | 16 | 2021 |
| Core polymer optimization of ternary siRNA nanoparticles enhances in vivo safety, pharmacokinetics, and tumor gene silencing SS Patel, EN Hoogenboezem, F Yu, CR DeJulius, RB Fletcher, AG Sorets, ... Biomaterials 297, 122098, 2023 | 9 | 2023 |
| Albumin-binding aptamer chimeras for improved siRNA bioavailability JC Rosch, EN Hoogenboezem, AG Sorets, CL Duvall, ES Lippmann Cellular and Molecular Bioengineering 15 (2), 161-173, 2022 | 8 | 2022 |
| Albumin-binding RNAi conjugate for carrier free treatment of arthritis JM Colazo, EN Hoogenboezem, MC Keech, N Francini, V Shah, F Yu, ... bioRxiv, 2023.05. 31.542971, 2023 | 6 | 2023 |
| Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy EN Hoogenboezem, SS Patel, JH Lo, AB Cavnar, LM Babb, N Francini, ... Nature Communications 15 (1), 1581, 2024 | 2 | 2024 |
| Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-targeted cancer therapy EN Hoogenboezem, SS Patel, AB Cavnar, JH Lo, LM Babb, N Francini, ... bioRxiv, 2023 | 2 | 2023 |
| Lipid-siRNA conjugate accesses a perivascular transport mechanism and achieves widespread and durable knockdown in the central nervous system A Sorets, K Schwensen, N Francini, A Kjar, A Abdulrahman, A Shostak, ... bioRxiv, 2024.06. 09.598079, 2024 | | 2024 |
| Therapeutic silencing of Rictor using siRNA nanoparticles to selectively block mTORC2 signaling in triple negative breast cancer SS Patel, EN Hoogenboezem, F Yu, AG Sorets, FK Cherry, JH Lo, ... Cancer Research 83 (7_Supplement), 2706-2706, 2023 | | 2023 |
| Albumin-Hitchhiking Mmp13 Sirna Conjugate (Simmp13<(Eg18l) 2) For The Treatment Of Rheumatic Disease JM Colazo, E Hoogenboezem, F Yu, V Shah, J Lo, H Cho, L Crofford, ... Osteoarthritis and Cartilage 31, S217, 2023 | | 2023 |
| Albumin-hitchhiking MMP13 siRNA Conjugate (siMMP13< (EG18L)2) for the Treatment of Rheumatic Disease J Colazo, E Hoogenboezem, F Yu, V Shah, J Lo, H Cho, K Hasty, ... ARTHRITIS & RHEUMATOLOGY 74, 4498-4501, 2022 | | 2022 |
| Development of Albumin-Hitchhiking siRNA Conjugates for Therapeutic Mcl-1 Silencing in Triple Negative Breast Cancer EN Hoogenboezem | | 2022 |
| Dual hydrophobization formulation strategies improve intravenous half-life, safety, and tumor delivery of siRNA nano-polyplexes M Jackson, S Bedingfield, F Yu, M Stokan, R Miles, E Hoogenboezem, ... EUROPEAN JOURNAL OF CANCER 103, E91-E91, 2018 | | 2018 |
